AR054617A1 - Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden - Google Patents
Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprendenInfo
- Publication number
- AR054617A1 AR054617A1 ARP060102461A ARP060102461A AR054617A1 AR 054617 A1 AR054617 A1 AR 054617A1 AR P060102461 A ARP060102461 A AR P060102461A AR P060102461 A ARP060102461 A AR P060102461A AR 054617 A1 AR054617 A1 AR 054617A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- arylheterocycloalkylalkyl
- heteroarylheterocycloalkylalkyl
- heteroarylcycloalkylalkyl
- heterocycloalkenylaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Además se revela la actividad inhibitoria de la aspartil proteasa.Composiciones farmacéuticas que los contienen. También se revelanel uso de estos para tratar enfermedades cognitivas o neurodegenerativas en combinacion con un inhibidor de colinesterasa o un agonista m1 o antagonista m2 muscarínico. Reivindicacion 1: Un compuesto que tiene la formula estructural (1) o su estereoisomero, tautomero o sal aceptable para uso farmacéutico, donde j es 0 o 1; k es 0 o 1, siempre que cuando k es 1, U no puede ser -N-; W es un enlace, -C(=S)-, -S(O)-, -S(O)2-, -C(=O)-, -O-, -C(R6)(R7)-, -N(R5)-, -C(R6)(R7)C(=O)-, o -C(=N(R5))-; U es -N- o -C(R6)-; R es 1-5 grupos R21; R1, R2 y R5 se seleccionan independientemente grupo integrado por H, alquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, heterocicloalquilalquilo, arilcicloalquilalquilo, heteroarilcicloalquilalquilo, arilheterocicloalquilalquilo, heteroarilheterocicloalquilalquilo, cicloalquilo, arilcicloalquilo, heteroarilcicloalquilo, heterocicloalquilo, arilheterocicloalquilo, heteroarilheterocicloalquilo, alquenilo, arilalquenilo, cicloalquenilo, arilcicloalquenilo, heteroarilcicloalquenilo, heterocicloalquenilo, arilheterocicloalquenilo, heteroarilheterocicloalquenilo, alquinilo, arilalquinilo, arilo, cicloalquilarilo, heterocicloalquilarilo, cicloalquenilarilo, heterocicloalquenilarilo, heteroarilo, cicloalquilheteroarilo, heterocicloalquilheteroarilo, cicloalquenilheteroarilo, heterocicloalquenilheteroarilo, -OR15, -CN, -C(=NR11)R8, -C(O)R8, -C(O)OR9, -S(O)R10, -S(O)2R10, -C(O)N(R11)(R12), -S(O)N(R11)(R12), -S(O)2N(R11)(R12), -NO2, -N=C(R8)2 y -N(R11)(R12), siempre que R1 y R5 no sean ambos seleccionados de -NO2, - N=C(R8)2 y -N(R11)(R12), R3, R6 y R7 se seleccionan independientemente del grupo integrado por H, alquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, heterocicloalquilalquilo, arilcicloalquilalquilo, heteroarilcicloalquilalquilo, arilheterocicloalquilalquilo, heteroarilheterocicloalquilalquilo, cicloalquilo, arilcicloalquilo, heteroarilcicloalquilo, heterocicloalquilo, arilheterocicloalquilo, heteroarilheterocicloalquilo, alquenilo, arilalquenilo, cicloalquenilo, arilcicloalquenilo, heteroarilcicloalquenilo, heterocicloalquenilo, arilheterocicloalquenilo, heteroarilheterocicloalquenilo, alquinilo, arilalquinilo, arilo, cicloalquilarilo, heterocicloalquilarilo, cicloalquenilarilo, heterocicloalquenilarilo, heteroarilo, cicloalquilheteroarilo, heterocicloalquilheteroarilo, cicloalquenilheteroarilo, heterocicloalquenilheteroarilo, halo, -CH2-O-Si(R9)(R10)(R19), -SH, -CN, -OR9, -C(O)R8, -C(O)OR9, -C(O)N(R11)(R12), -SR19, -S(O)N(R11)(R12), - S(O)2N(R11)(R12), -N(R11)(R12), -N(R11)C(O)R8, -N(R11)S(O)R10, -N(R11)S(O)2R10-, -N(R11)C(O)N(R12)(R13), -N(R11)C(O)OR9 y -C(=NOH)R8; R4 y R7a se seleccionan independientemente del grupo integrado por un enlace, alquileno, arilalquileno, heteroarilalquileno, cicloalquilalquileno, heterocicloalquilalquileno, arilcicloalquilalquileno, heteroarilcicloalquilalquileno, arilheterocicloalquilalquileno, heteroarilheterocicloalquilalquileno, cicloalquileno, arilcicloalquileno, heteroarilcicloalquileno, heterocicloalquileno, arilheterocicloalquileno, heteroarilheterocicloalquileno, alquenileno, arilalquenileno, cicloalquenileno, arilcicloalquenileno, heteroarilcicloalquenileno, heterocicloalquenileno, arilheterocicloalquenileno, heteroarilheterocicloalquenileno, alquinileno, arilalquinileno, arileno, cicloalquilarileno, heterocicloalquilarileno, cicloalquenilarileno, cicloalquenilarileno, heterocicloalquenilarileno, heteroarileno, cicloalquilheteroarileno, heterocicloalquilheteroarileno, cicloalquenilheteroarileno y heterocicloalquenilheteroarileno, siempre que ambos R4 y R7no sean un enlace; R4 y R7a juntos pueden ser una cadena de carbonos C1 a C8, donde, opcionalmente, uno, dos o tres carbonos del anillo pueden ser reemplazados por -O-, -C(O)-, -C(S)-, -S-,-S(O), -S(O)2- o -N(R5)-, y R4 y R7a junto con los átomos de C a los cuales están unidos, forman un anillo de 3 a 8 miembros, opcionalmente sustituido con R; con las siguientes salvedades: que cuando al menos uno de los C es reemplazado por -O-, -C(O)-, -C(S)-, -S-, -S(O)-, -S(O)2- o -N(R5)-; entonces el numero de C en la porcion R4 y R7a de la cadena que se une con U es b, donde b es 0 a 5, y el numero de C que están en la porcion de R4 y R7a de la cadena que se une con el C de -C(R3)- es c, donde c es 0 a 5; que cuando j es 0 o 1, al menos uno de los átomos en el anillo debe estar reemplazado por -O-, -C(O)-, -C(S)-, -S-, -S(O)-, -S(O)2- o -N(R5)- ; que cuando j es 0 o 1 y solo un C en el anillo está reemplazado con -O-, -C(O)-, -C(S)-, -S-, -S(O)-, -S(O)2- o -N(R5)-, R4 y R7a no pueden formar un cicloalquiléter; R8 se selecciona independientemente del grupo integrado por H, alquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, heterocicloalquilalquilo, arilcicloalquilalquilo, heteroarilcicloalquilalquilo, arilheterocicloalquilalquilo, heteroarilheterocicloalquilalquilo, cicloalquilo, arilcicloalquilo, heteroarilcicloalquilo, heterocicloalquilo, arilheterocicloalquilo, heteroarilheterocicloalquilo, alquenilo, arilalquenilo, cicloalquenilo, arilcicloalquenilo, heteroarilcicloalquenilo, heterocicloalquenilo, arilheterocicloalquenilo, heteroarilheterocicloalquenilo, alquinilo, arilalquinilo, arilo, cicloalquilarilo, heterocicloalquilarilo, cicloalquenilarilo, heterocicloalquenilarilo, heteroarilo, cicloalquilheteroarilo, heterocicloalquilheteroarilo, cicloalquenilheteroarilo, heterocicloalquenilheteroarilo, -OR15, -N(R15)(R16), -N(R15)C(O)R16, -N(R15)S(O)R16, -N(R15)S(O)2R16, N(R15)S(O)2N(R16)(R17), -N(R15)S(O)N(R16)(R17), -N(R15)C(O)N(R16)(R17), y -N(R15)C(O)OR16; R9 se selecciona independientemente del grupo integrado por H, alquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, heterocicloalquilalquilo, arilcicloalquilalquilo, heteroarilcicloalquilalquilo, arilheterocicloalquilalquilo, heteroarilheterocicloalquilalquilo, cicloalquilo, arilcicloalquilo, heteroarilcicloalquilo, heterocicloalquilo, arilheterocicloalquilo, heteroarilheterocicloalquilo, alquenilo, arilalquenilo, cicloalquenilo, arilcicloalquenilo, heteroarilcicloalquenilo, heterocicloalquenilo, arilheterocicloalquenilo, heteroarilheterocicloalquenilo, alquinilo, arilalquinilo, arilo, cicloalquilarilo, heterocicloalquilarilo, cicloalquenilarilo, heterocicloalquenilarilo, heteroarilo, cicloalquilheteroarilo, heterocicloalquilheteroarilo, cicloalquenilheteroarilo, y heterocicloalquenilheteroarilo; R10 se selecciona independientemente del grupo integrado por H, alquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, heterocicloalquilalquilo, arilcicloalquilalquilo, heteroarilcicloalquilalquilo, arilheterocicloalquilalquilo, heteroarilheterocicloalquilalquilo, cicloalquilo, arilcicloalquilo, heteroarilcicloalquilo, heterocicloalquilo, arilheterocicloalquilo, heteroarilheterocicloalquilo, alquenilo, arilalquenilo, cicloalquenilo, arilcicloalquenilo, heteroarilcicloalquenilo, heterocicloalquenilo, arilheterocicloalquenilo, heteroarilheterocicloalquenilo, alquinilo, arilalquinilo, arilo, cicloalquilarilo, heterocicloalquilarilo, cicloalquenilarilo, heterocicloalquenilarilo, heteroarilo, cicloalquilheteroarilo, heterocicloalquilheteroarilo, cicloalquenilheteroarilo, heterocicloalquenilheteroarilo, y -N(R15)(R16); R11, R12 y R13 se seleccionan independientemente del grupo integrado por H, alquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, heterocicloalquilalquilo, arilcicloalquilalquilo, heteroarilcicloalquilalquilo, arilheterocicloalquilalquilo, heteroarilheterocicloalquilalquilo, cicloalquilo, arilcicloalquilo, heteroarilcicloalquilo, heterocicloalquilo, arilheterocicloalquilo, heteroarilheterocicloalquilo, alquenilo, arilalquenilo, cicloalquenilo, arilcicloalquenilo, heteroarilcicloalquenilo, heterocicloalquenilo, arilheterocicloalquenilo, heteroarilheterocicloalquenilo, alquinilo, arilalquinilo, arilo, cicloalquilarilo, heterocicloalquilarilo, cicloalquenilarilo, heterocicloalquenilarilo, heteroarilo, cicloalquilheteroarilo, heterocicloalquilheteroarilo, cicloalquenilheteroarilo, heterocicloalquenilheteroarilo, - C(O)R8, -C(O)OR9, -S(O)R10, -S(O)2R10, -C(O)N(R11)(R12), -S(O)N(R11)(R12), -S(O)2N(R11)(R12), y -CN; R15, R16 y R17 se seleccionan independientemente del grupo integrado por H, alquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo, heterocicloalquilalquilo, arilcicloalquilalquilo, heteroarilcicloalquilalquilo, arilheterocicloalquilalquilo, heteroarilheterocicloalquilalquilo, cicloalquilo, arilcicloalquilo, heteroarilcicloalquilo, heterocicloalquilo, arilheterocicloalquilo, heteroarilheterocicloalquilo, alquenilo, arilalquenilo, cicloalquenilo, arilcicloalquenilo, heteroarilcicloalquenilo, heterocicloalquenilo, arilheterocicloalquenilo, heteroarilheterocicloalquenilo, alquinilo, arilalquinilo, arilo, cicloalquilarilo, heterocicloalquilarilo, cicloalquenilarilo, heterocicloalquenilarilo, heteroarilo, cicloalquilheteroarilo, heterocicloalquilheteroarilo, cicloalquenilheteroarilo, heterocicloalquenilheteroarilo, R18-alquilo, R18-arilalquilo, R18-heteroarilalquilo, R18-cicloalquilalquilo, R18-heterocicloalquilalquilo, R18-arilcicloalquilalquilo, R18-heteroarilcicloalquilalquilo, R18-arilheterocicloalquilalquilo, R18-heteroarilheterocicloalquilalquilo, R18-cicloalquilo, R18arilcicloalquilo, R18- heteroarilcicloalquilo, R18-heterocicloalquilo, R18-arilheterocicloalquilo, R18-heteroarilheterocicloalquilo, R18-alquenilo, R18-arilalquenilo, R18-cicloalquenilo, R18-arilcicloalquenilo, R18-heteroarilcicloalquenilo, R18-heterocicloalquenilo, R18- arilheterocicloalquenilo, R18-heteroarilheterocicloalquenilo, R18-alquinilo, R18-arilalquinilo, R18-arilo, R18-cicloalquilarilo, R18-heterocicloalquilarilo, R18-cicloalquenilarilo, R18-heterocicloalquenilarilo, R18-heteroarilo, R18- cicloalquilheteroarilo, R18-heterocicloalquilheteroarilo, R18-cicloalquenilheteroarilo y R18-hete
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69053705P | 2005-06-14 | 2005-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054617A1 true AR054617A1 (es) | 2007-07-04 |
Family
ID=37114557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060102461A AR054617A1 (es) | 2005-06-14 | 2006-06-12 | Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden |
Country Status (18)
Country | Link |
---|---|
US (1) | US7868000B2 (es) |
EP (1) | EP1896478B1 (es) |
JP (2) | JP2008543849A (es) |
KR (1) | KR20080029965A (es) |
CN (1) | CN101228163A (es) |
AR (1) | AR054617A1 (es) |
AU (1) | AU2006259572A1 (es) |
BR (1) | BRPI0612072A2 (es) |
CA (1) | CA2609582A1 (es) |
EC (1) | ECSP078003A (es) |
IL (1) | IL187814A0 (es) |
MX (1) | MX2007016180A (es) |
NO (1) | NO20080187L (es) |
PE (1) | PE20070135A1 (es) |
RU (1) | RU2008100165A (es) |
SG (1) | SG162790A1 (es) |
TW (2) | TWI332005B (es) |
WO (1) | WO2006138264A2 (es) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0220581D0 (en) * | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
PE20060437A1 (es) * | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
AR054617A1 (es) | 2005-06-14 | 2007-07-04 | Schering Corp | Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden |
US7759354B2 (en) * | 2005-06-14 | 2010-07-20 | Schering Corporation | Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof |
AU2006259573A1 (en) * | 2005-06-14 | 2006-12-28 | Pharmacopeia, Inc. | Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
GB0521508D0 (en) * | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
CN101296926A (zh) | 2005-10-27 | 2008-10-29 | 先灵公司 | 天冬氨酰蛋白酶抑制剂 |
GB0525672D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525673D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
WO2007146225A2 (en) | 2006-06-12 | 2007-12-21 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
AU2007332750A1 (en) * | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors containing a tricyclic ring system |
KR20090087487A (ko) * | 2006-12-12 | 2009-08-17 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
WO2009032277A1 (en) | 2007-09-06 | 2009-03-12 | Schering Corporation | Gamma secretase modulators |
JP2011503002A (ja) | 2007-11-05 | 2011-01-27 | シェーリング コーポレイション | γセクレターゼ調節剤 |
CN101945868A (zh) | 2007-12-11 | 2011-01-12 | 先灵公司 | γ分泌酶调节剂 |
TW201004957A (en) * | 2008-04-22 | 2010-02-01 | Schering Corp | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use |
JP5503663B2 (ja) | 2008-11-13 | 2014-05-28 | メルク・シャープ・アンド・ドーム・コーポレーション | ガンマセクレターゼモジュレータ |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
CA2747750A1 (en) | 2008-12-22 | 2010-07-01 | Theodros Asberom | Gamma secretase modulators |
US8759337B2 (en) | 2008-12-22 | 2014-06-24 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
FR2944011B1 (fr) | 2009-04-03 | 2011-05-20 | Pf Medicament | Derives d'aminocyclobutane ou d'aminocyclobutene, leur procede de preparation et leur utilisation a titre de medicaments. |
US20120232108A1 (en) | 2009-06-16 | 2012-09-13 | Xianhai Huang | Gamma secretase modulators |
US20120245158A1 (en) | 2009-06-16 | 2012-09-27 | Xianhai Huang | Gamma secretase modulators |
WO2010147969A2 (en) | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
GB0912777D0 (en) * | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
EP2281824A1 (en) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
EP2485591B1 (en) | 2009-10-08 | 2016-03-23 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
WO2011044184A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
WO2011071109A1 (ja) * | 2009-12-11 | 2011-06-16 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
EP2643299B1 (en) | 2010-11-22 | 2016-06-22 | Noscira, S.A. | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions |
US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
SG10201601516QA (en) | 2011-01-21 | 2016-03-30 | Eisai R&D Man Co Ltd | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
WO2012138590A1 (en) * | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
CA2844988A1 (en) | 2011-08-22 | 2013-02-28 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono- and dioxides as bace inhibitors, compositions, and their use |
US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
CN106902108B (zh) | 2012-03-19 | 2020-07-21 | 巴克老龄化研究所 | App特异性bace抑制剂(asbi)及其用途 |
JO3143B1 (ar) * | 2012-04-03 | 2017-09-20 | Lilly Co Eli | مركبات تتراهيدرو بيرولو ثيازين |
WO2013180265A1 (ja) | 2012-06-01 | 2013-12-05 | 武田薬品工業株式会社 | 複素環化合物 |
US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US10548882B2 (en) | 2012-06-21 | 2020-02-04 | Astrazeneca Ab | Camsylate salt |
WO2014062549A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US9416129B2 (en) | 2012-10-17 | 2016-08-16 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use |
CA2886507C (en) | 2012-10-26 | 2016-09-20 | Eli Lilly And Company | Bace inhibitors |
EP2934534B1 (en) | 2012-12-21 | 2017-12-13 | Merck Sharp & Dohme Corp. | C5-spiro iminothiadiazine dioxides as bace inhibitors |
CN104995176B (zh) | 2013-02-12 | 2019-02-22 | 巴克老龄化研究所 | 调节bace所介导的app加工的乙内酰脲 |
TWI593692B (zh) * | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
US9745324B2 (en) | 2013-12-18 | 2017-08-29 | Merck Sharp & Dohme Corp. | Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use |
AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
CN104761557B (zh) * | 2015-04-08 | 2017-02-22 | 河南师范大学 | 六氢‑1H‑吡咯并[3,4‑d]嘧啶类化合物及其制备方法 |
AR104241A1 (es) | 2015-04-29 | 2017-07-05 | Lilly Co Eli | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |
WO2017139209A1 (en) | 2016-02-11 | 2017-08-17 | Merck Sharp & Dohme Corp. | C5-c6-oxacylic fused iminothiazine dioxide compounds bearing an ether linker as bace inhibitors, compositions, and their use |
CN107892697B (zh) | 2016-12-26 | 2020-11-03 | 郑州泰基鸿诺医药股份有限公司 | 一种[1,3]噻嗪-2-胺类化合物及应用,药物组合物 |
CA3088000A1 (en) | 2018-02-28 | 2019-09-06 | Japan Tobacco Inc. | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL92011A0 (en) | 1988-10-19 | 1990-07-12 | Abbott Lab | Heterocyclic peptide renin inhibitors |
AU2436792A (en) * | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
US5610294A (en) * | 1991-10-11 | 1997-03-11 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors |
IT1270008B (it) | 1994-09-23 | 1997-04-16 | Ist Superiore Sanita | Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
US5935958A (en) | 1996-07-01 | 1999-08-10 | Schering Corporation | Muscarinic antagonists |
US5952349A (en) | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
US5977138A (en) | 1996-08-15 | 1999-11-02 | Schering Corporation | Ether muscarinic antagonists |
EP1086076B1 (en) * | 1998-06-19 | 2004-12-22 | Vertex Pharmaceuticals Incorporated | Sulfonamide inhibitors of aspartyl protease |
US6066636A (en) | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
US6492408B1 (en) | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
US6294554B1 (en) | 1999-09-22 | 2001-09-25 | Schering Corporation | Muscarinic antagonists |
US6414161B1 (en) | 2000-08-09 | 2002-07-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis of (R)-3-(4-Bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-H-imidazo[1,2-a]imidazol-2-one |
JP4012068B2 (ja) | 2000-12-22 | 2007-11-21 | シェーリング コーポレイション | ムスカリンアンタゴニスト |
AU2002306734A1 (en) | 2001-03-15 | 2002-10-03 | The Johns Hopkins University | Inhibitors of plasmepsins |
ES2269774T3 (es) | 2001-10-10 | 2007-04-01 | Schering Corporation | Compuestos de piperidina como antagonistas muscarinicos. |
TW200524910A (en) | 2003-08-08 | 2005-08-01 | Schering Corp | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent |
WO2005016876A2 (en) | 2003-08-08 | 2005-02-24 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
US20050171112A1 (en) | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
MXPA06006730A (es) * | 2003-12-15 | 2006-08-31 | Schering Corp | Inhibidores de aspartil proteasa heterociclicos. |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
EP1740573A1 (en) | 2004-04-22 | 2007-01-10 | Eli Lilly And Company | Amides as bace inhibitors |
ES2332659T3 (es) * | 2004-06-16 | 2010-02-10 | Wyeth | Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa. |
WO2006009655A1 (en) * | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase |
CN101014577A (zh) | 2004-07-22 | 2007-08-08 | 先灵公司 | 取代的酰胺β分泌酶抑制剂 |
CA2575340A1 (en) | 2004-07-28 | 2006-02-09 | Schering Corporation | Macrocyclic beta-secretase inhibitors |
EP1789398B1 (en) | 2004-08-06 | 2010-09-29 | Janssen Pharmaceutica NV | 2-amino-quinazoline derivatives useful as inhibitors of b-secretase (bace) |
ES2403185T3 (es) | 2004-08-06 | 2013-05-16 | Janssen Pharmaceutica N.V. | Nuevos derivados de 2-amino-quinazolina útiles como inhibidores de ss-secretasa (BACE) |
US8436006B2 (en) | 2004-08-06 | 2013-05-07 | Jansssen Pharmaceutica N.V. | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) |
WO2006044492A2 (en) | 2004-10-14 | 2006-04-27 | Ingenious Targeting Laboratory, Inc. | Methods for generating rat embryo-derived cell lines and genetic modification of rat genome |
EP1802587A4 (en) | 2004-10-15 | 2010-02-17 | Astrazeneca Ab | SUBSTITUTED AMINO BINDINGS AND THEIR APPLICATIONS |
WO2006041405A1 (en) | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-pyrimidones and uses thereof |
EP2264036A1 (en) | 2005-01-14 | 2010-12-22 | Wyeth LLC (Formerly Known As Wyeth) | Amino-imidazolones for the inhibition of beta-secretase |
JP2008543846A (ja) | 2005-06-14 | 2008-12-04 | シェーリング コーポレイション | プロテアーゼ阻害剤として化合物の調製およびその使用 |
WO2006138195A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Macrocyclic heterocyclic aspartyl protease inhibitors |
AR054617A1 (es) | 2005-06-14 | 2007-07-04 | Schering Corp | Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden |
AR054510A1 (es) | 2005-06-14 | 2007-06-27 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil proteasas y composiciones farmaceuticas que los comprenden. |
AU2006259573A1 (en) | 2005-06-14 | 2006-12-28 | Pharmacopeia, Inc. | Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
US7759354B2 (en) | 2005-06-14 | 2010-07-20 | Schering Corporation | Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof |
WO2006138217A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
WO2007005404A1 (en) * | 2005-06-30 | 2007-01-11 | Wyeth | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
TW200738683A (en) * | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
TW200730523A (en) * | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
BRPI0616757A2 (pt) * | 2005-09-26 | 2011-06-28 | Wyeth Corp | composto da fórmula i; processo para o tratamento de uma doença ou de um distúrbio associado com a atividade excessiva de bace; processo para a modulação da atividade de bace; processo para o tratamento da doença de alzheimer; e composição farmacêutica |
EP1942105B8 (en) | 2005-10-25 | 2014-08-13 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivative |
DE602006020773D1 (de) * | 2005-10-25 | 2011-04-28 | Janssen Pharmaceutica Nv | Als inhibitoren von beta-sekretase (bace) geeignete 2-amino-3,4-dihydropyridoä3,4-düpyrimidinderivate |
CN101296926A (zh) | 2005-10-27 | 2008-10-29 | 先灵公司 | 天冬氨酰蛋白酶抑制剂 |
CA2628264A1 (en) * | 2005-10-31 | 2007-05-10 | Schering Corporation | Aspartyl protease inhibitors |
US20080318985A1 (en) | 2005-11-15 | 2008-12-25 | Astrazeneca Ab | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use |
US20090215801A9 (en) | 2005-11-15 | 2009-08-27 | Astrazeneca Ab, Sodertaije, Swedenastex Thereapeutics Ltd | Novel 2-Aminopyrimidinone Derivatives And Their Use |
TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
JP2009520686A (ja) | 2005-11-21 | 2009-05-28 | アストラゼネカ・アクチエボラーグ | 新規な2−アミノ−イミダゾール−4−オン化合物並びに認知障害、アルツハイマー病、神経変性及び認知症の治療に使用する医薬の製造におけるその使用 |
JP2009520027A (ja) | 2005-12-19 | 2009-05-21 | ワイス | 2−アミノ−5−ピペリジニルイミダゾロン化合物およびβ−セクレターゼ調節におけるその使用 |
AR058381A1 (es) | 2005-12-19 | 2008-01-30 | Astrazeneca Ab | Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica |
WO2007092854A2 (en) | 2006-02-06 | 2007-08-16 | Janssen Pharmaceutica N.V. | 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
WO2007092839A2 (en) | 2006-02-06 | 2007-08-16 | Janssen Pharmaceutica N.V. | Macrocycle derivatives useful as inhibitors of beta-secretase (bace) |
US7776882B2 (en) * | 2006-02-06 | 2010-08-17 | Baxter Ellen W | 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
WO2007100536A1 (en) * | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
JP2009532464A (ja) | 2006-04-05 | 2009-09-10 | アストラゼネカ・アクチエボラーグ | 2−アミノピリミジン−4−オン及びAβ−関連の病理を治療又は予防するためのその使用 |
WO2007146225A2 (en) * | 2006-06-12 | 2007-12-21 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
TW200815449A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds II |
TW200815443A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds I |
US20080051420A1 (en) * | 2006-06-14 | 2008-02-28 | Astrazeneca Ab | New Compounds 317 |
TW200815447A (en) * | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
TW200808796A (en) | 2006-06-14 | 2008-02-16 | Astrazeneca Ab | New compounds III |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
TW200817406A (en) | 2006-08-17 | 2008-04-16 | Wyeth Corp | Imidazole amines as inhibitors of β-secretase |
WO2008063114A1 (en) | 2006-11-20 | 2008-05-29 | Astrazeneca Ab | Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia |
AU2007332750A1 (en) * | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors containing a tricyclic ring system |
KR20090087487A (ko) * | 2006-12-12 | 2009-08-17 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
WO2008076044A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5, 5-diaryl-imidazol-4-ones |
TW200831484A (en) * | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
CL2008000784A1 (es) | 2007-03-20 | 2008-05-30 | Wyeth Corp | Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co |
CL2008000791A1 (es) | 2007-03-23 | 2008-05-30 | Wyeth Corp | Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm |
US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
KR20100017255A (ko) | 2007-04-24 | 2010-02-16 | 시오노기 앤드 컴파니, 리미티드 | 환식기로 치환된 아미노다이하이드로싸이아진 유도체 |
UY31083A1 (es) * | 2007-05-15 | 2009-01-05 | Astrazeneca Ab | Derivados de sulfoximinas para la inhibicion de b-secretasa |
TW200902499A (en) * | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
WO2009005471A1 (en) | 2007-07-05 | 2009-01-08 | Astrazeneca Ab | Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors |
WO2009005470A1 (en) | 2007-07-05 | 2009-01-08 | Astrazeneca Ab | Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors |
JP5450407B2 (ja) | 2007-07-06 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法 |
KR101564634B1 (ko) | 2008-01-18 | 2015-10-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 축합 아미노디하이드로 티아진 유도체 |
CL2009000119A1 (es) | 2008-01-22 | 2010-03-05 | Boehringer Ingelheim Int | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. |
WO2009097278A1 (en) | 2008-01-28 | 2009-08-06 | Janssen Pharmaceutica N.V. | 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
AU2009209147B2 (en) | 2008-01-29 | 2013-03-14 | Janssen Pharmaceutica Nv | 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (BACE) |
KR101259240B1 (ko) * | 2008-02-18 | 2013-04-29 | 시에나 바이오테크 에스.피.에이. | 4,5-다이하이드로-옥사졸-2-일 아민 유도체 |
TW201004957A (en) | 2008-04-22 | 2010-02-01 | Schering Corp | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use |
TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
EP2318416B1 (en) | 2008-07-28 | 2013-09-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
TW201016708A (en) | 2008-09-30 | 2010-05-01 | Eisai R&D Man Co Ltd | Novel fused aminodihydrothiazine derivative |
EP2360155A4 (en) | 2008-10-22 | 2012-06-20 | Shionogi & Co | 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT |
US20100125081A1 (en) | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | New compounds 574 |
WO2010059953A1 (en) | 2008-11-20 | 2010-05-27 | Purdue Research Foundation | Quinazoline inhibitors of bace 1 and methods of using |
-
2006
- 2006-06-12 AR ARP060102461A patent/AR054617A1/es not_active Application Discontinuation
- 2006-06-12 US US11/451,541 patent/US7868000B2/en active Active
- 2006-06-12 CN CNA2006800215030A patent/CN101228163A/zh active Pending
- 2006-06-12 PE PE2006000655A patent/PE20070135A1/es not_active Application Discontinuation
- 2006-06-12 CA CA002609582A patent/CA2609582A1/en not_active Abandoned
- 2006-06-12 KR KR1020077029300A patent/KR20080029965A/ko not_active Application Discontinuation
- 2006-06-12 JP JP2008516997A patent/JP2008543849A/ja active Pending
- 2006-06-12 BR BRPI0612072-5A patent/BRPI0612072A2/pt not_active IP Right Cessation
- 2006-06-12 MX MX2007016180A patent/MX2007016180A/es active IP Right Grant
- 2006-06-12 RU RU2008100165/04A patent/RU2008100165A/ru not_active Application Discontinuation
- 2006-06-12 WO PCT/US2006/022918 patent/WO2006138264A2/en active Application Filing
- 2006-06-12 SG SG201004170-5A patent/SG162790A1/en unknown
- 2006-06-12 TW TW095120854A patent/TWI332005B/zh active
- 2006-06-12 EP EP06784807.7A patent/EP1896478B1/en active Active
- 2006-06-12 TW TW098137006A patent/TW201004961A/zh unknown
- 2006-06-12 AU AU2006259572A patent/AU2006259572A1/en not_active Abandoned
-
2007
- 2007-12-02 IL IL187814A patent/IL187814A0/en unknown
- 2007-12-12 EC EC2007008003A patent/ECSP078003A/es unknown
-
2008
- 2008-01-11 NO NO20080187A patent/NO20080187L/no not_active Application Discontinuation
- 2008-03-05 JP JP2008055596A patent/JP2008201784A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2006138264A3 (en) | 2007-03-01 |
NO20080187L (no) | 2008-03-14 |
BRPI0612072A2 (pt) | 2010-10-19 |
IL187814A0 (en) | 2008-08-07 |
EP1896478B1 (en) | 2014-05-21 |
CA2609582A1 (en) | 2006-12-28 |
JP2008201784A (ja) | 2008-09-04 |
TW200716642A (en) | 2007-05-01 |
MX2007016180A (es) | 2008-03-07 |
PE20070135A1 (es) | 2007-03-09 |
TW201004961A (en) | 2010-02-01 |
US20070060575A1 (en) | 2007-03-15 |
TWI332005B (en) | 2010-10-21 |
KR20080029965A (ko) | 2008-04-03 |
CN101228163A (zh) | 2008-07-23 |
WO2006138264A2 (en) | 2006-12-28 |
US7868000B2 (en) | 2011-01-11 |
EP1896478A2 (en) | 2008-03-12 |
AU2006259572A1 (en) | 2006-12-28 |
SG162790A1 (en) | 2010-07-29 |
JP2008543849A (ja) | 2008-12-04 |
RU2008100165A (ru) | 2009-07-20 |
ECSP078003A (es) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054617A1 (es) | Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden | |
AR054620A1 (es) | Inhibidores de aspartil proteasas | |
AR061264A1 (es) | Inhibidores de aspartil-proteasas derivados de pirimidina, composiciones farmaceuticas que los contienen y usos para tratar enfermedades cognitivas o neurodegenerativas, y como inhibidores del virus vih. | |
AR054619A1 (es) | Inhibidores de aspartil proteasas | |
AR056211A1 (es) | Derivados de [1,4,6]oxadiazepinas, composiciones farmaceuticas que los contienen en combinacion con otros agentes terapeuticos y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de aspartil-proteasas | |
AR054618A1 (es) | Compuestos de azetidina y su uso como inhibidores de proteasas | |
AR054510A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas y composiciones farmaceuticas que los comprenden. | |
AR064601A1 (es) | Inhibidores de la aspartil proteasa | |
AR057983A1 (es) | Inhibidores hterociclicos de aspartil proteasas | |
AR065421A1 (es) | Inhibidores heterociclicos de la aspartil proteasa | |
AR064287A1 (es) | Inhibidores de aspartil protesa | |
AR053436A1 (es) | Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas | |
AR078540A1 (es) | Compuestos heterociclicos utiles como inhibidores de pdk1 | |
AR076830A1 (es) | Compuestos de carboxamidas de imidazol como moduladores de trpv3 | |
AR047050A1 (es) | Derivados de 1,3 diazol como inhibidores de aspartilproteasa. composiciones farmacéuticas | |
NI200700102A (es) | Derivados de indol tetraciclicos como agentes antiviricos | |
AR062224A1 (es) | Tetrazolilos macrociclicos como inhibidores de serina proteasa ns3 del virus de hepatitis c y composiciones farmaceuticas que los comprenden. | |
AR056865A1 (es) | Heterociclos nitrogenados y su uso como inhibidores de proteasas, composiciones farmaceuticas | |
AR057023A1 (es) | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa | |
AR058919A1 (es) | Compuestos de heteroarilo biciclicos como inhibidores de pde10, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades del snc. | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR042996A1 (es) | Un procedimiento de obtencion de derivados de malonamida y medicamentos que los contienen. | |
AR052771A1 (es) | Pirimidinas biciclicas inhibidoras del vhc | |
AR053713A1 (es) | Compuestos heterociclicos y sus usos como agentes terapeuticos | |
ES2354569T3 (es) | Antagonistas del receptor de histamina-3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |